Boston Scientific Corp (BSX) Stock AnalysisBSXBoston Scientific Corp

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Boston Scientific is not a good buy right now due to significant recent declines and negative news. The stock is currently priced at $46.84, down 56% over the past year, and has an RSI of 31.141, indicating it is oversold. Additionally, insider selling has increased by 755.62%, suggesting a lack of confidence among company executives. The main risk is the recent cyberattack that has disrupted operations, which could further impact the stock's recovery.

24 analysts cover BSX: 18 rate it Buy, 6 Hold and 0 Sell. The average price target is 108.14.